(Reuters) – The U.S. Food and Drug Administration’s (FDA) staff on Wednesday pointed to “notable imbalance” in incidence of low blood sugar in patients with type 1 diabetes treated with Danish drugmaker Novo Nordisk’s long-acting weekly insulin.
A panel of independent FDA advisers will meet on Friday to review and discuss the safety and effectiveness of Novo’s insulin, icodec — an under-the-skin injection.
(Reporting by Mariam Sunny and Sriparna Roy in Bengaluru; Editing by Tasim Zahid and Shilpi Majumdar)
Comments